UniQure  (QURE) - Get Report  jumped Monday after a report said the biotechnology company was exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

The stock rose 6% to $76.89. UniQure has a market cap of $2.73 billion

UniQure is working with advisers as it weighs options including a sale or partnerships, Bloomberg reported, citing people with knowledge of the matter.

Cantor Fitzgerald in February noted that UniQure may attract interest from large-cap companies such as Novo Nordisk (NVO) - Get Report , Pfizer (PFE) - Get Report and Sanofi (SNY) - Get Report .

UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn't renew its marketing authorization in 2017. Since then, the company has focused on hemophilia treatments, according to Bloomberg.